Bruker winds down underperforming instrument lines


Instrument heavyweight Bruker is winding down its range of stand-alone gas chromatography (GC), inductively-coupled plasma mass spectrometry (ICP-MS) and single quadrupole GC-MS instruments. In a statement, the company said that its Chemical and Applied Markets division, which houses these products, has generated significant losses for the last four years, with little prospect of near-term profitability.

Bruker will honour outstanding orders for the affected GC and GC-MS instruments, but is not taking any new orders. The company is looking to sell off its ICP-MS business, and for someone to take over the service contracts for the GC instruments. The firm will retain support for GC-MS systems, as it continues to sell instruments with triple-quadrupole mass detectors.

At the same time, the company is expanding its microscopy offering in the life sciences, by acquiring US start-up Vutara for its high speed, 3D, super resolution fluorescence microscopy technology. The companies did not disclose financial details of the transaction.


Related Content

X marks the structure

31 October 2014 Review

news image

Elisabeth Jeffries discovers there’s a diffractometer for everything from crystals to proteins

A close look at microscopy

5 November 2013 Review

news image

Elisabeth Jeffries zooms in on scanning probe microscopy and other techniques

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Grad student blamed for research misconduct at Utah

13 November 2014 News and Analysis

news image

Two papers have been retracted due to image falsification at the University of Utah

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company